Amendments to the Specification

Please replace the previous Sequence Listing with the new Sequence Listing submitted herewith.

Please replace the paragraph beginning at page 15, line 18 with the following replacement paragraph.

-- Figure 8C illustrates that the DR-3 element is essential for SXR-mediated activation of CYP3A2, and is interchangeable with the IR-6 element. The wild type (DR3/WT (SEQ ID NO:39), filled bars) or mutant forms (DR3/M1 (SEQ ID NO:42), open bars; DR3/M2 (SEQ ID NO:43), stippled bars; and DR3/IR6 **(SEQ ID NO:24)**, hatched bars) of CYP3A23 cellular promoter reporters were transfected into primary rat hepatocytes in the presence of expression vector for SXR. The ligand treatment and data presentation are the same as in 8A. RIF, rifampicin; CTZ, clotrimazole. Note the disruptions of DR-3 element (DR3/M1, and DR3/M2) abrogate the activation of CYP3A23, and the replacement of DR-3 element with IR-6 element (DR3/IR3) rescue the responsiveness. --

Please replace the paragraph beginning at page 23, line 12 with the following replacement paragraph.

-- Examples of response elements suitable for use in practice of the invention methods can be selected from the following:

DR-3,4,5=AGGTCAN_nAGGTCA, wherein n is 3 ~~(SEQ ID NO: 44)~~, 4 ~~(SEQ ID NO: 45)~~, or 5 **(SEQ ID NO:44)**~~(SEQ ID NO: 46)~~;

βDR-3,4,5=AGTTCAN_nTGAACT, wherein n is 3**, 4 or 5** (SEQ ID NO:22); ~~4 (SEQ ID NO: 47) or 5 (SEQ ID NO: 48)~~ and

IR-6 = TGAACTN_nAGGTCA, wherein n is 6 (SEQ ID NO: 23), and the like. --